Anacor Starts Phase IIB Trial of Psoriasis Treatment

Anacor Pharmaceuticals announced that the first patient has been dosed in a Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis.

Anacor Pharmaceuticals has dosed the first patient in a Phase IIb trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

The double-blind, randomised and vehicle-controlled study is designed to evaluate the safety and efficacy of AN2728 in patients with mild to moderate plaque-type psoriasis.

The trial will enrol 60 patients who will be randomised to 2% AN2728 topical ointment or vehicle in a 2:1 ratio. The trial will determine the size and design of the two planned pivotal Phase III trials of AN2728.

 <